146 related articles for article (PubMed ID: 19852742)
1. Diagnostic markers and prognostic factors in thyroid cancer.
Vriens MR; Schreinemakers JM; Suh I; Guerrero MA; Clark OH
Future Oncol; 2009 Oct; 5(8):1283-93. PubMed ID: 19852742
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in the clinical application of thyroid cancer biomarkers.
Shibru D; Chung KW; Kebebew E
Curr Opin Oncol; 2008 Jan; 20(1):13-8. PubMed ID: 18043251
[TBL] [Abstract][Full Text] [Related]
3. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.
Eszlinger M; Paschke R
Mol Cell Endocrinol; 2010 Jun; 322(1-2):29-37. PubMed ID: 20083161
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of thyroid cancer: state of art.
Boufraqech M; Patel D; Xiong Y; Kebebew E
Expert Opin Med Diagn; 2013 Jul; 7(4):331-42. PubMed ID: 23701167
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms.
Kebebew E; Peng M; Reiff E; McMillan A
Cancer; 2006 Jun; 106(12):2592-7. PubMed ID: 16688775
[TBL] [Abstract][Full Text] [Related]
6. An update on molecular biology of thyroid cancers.
Omur O; Baran Y
Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
[TBL] [Abstract][Full Text] [Related]
7. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients.
Cañadas-Garre M; Becerra-Massare P; López de la Torre-Casares M; Villar-del Moral J; Céspedes-Mas S; Vílchez-Joya R; Muros-de Fuentes T; García-Calvente C; Piédrola-Maroto G; López-Nevot MA; Montes-Ramírez R; Llamas-Elvira JM
Ann Surg; 2012 May; 255(5):986-92. PubMed ID: 22504197
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic value of BRAFV600E and RET/PTC oncogenes in thyroid nodule aspirates].
Guerra A; Carrano M; Angrisani E; Vitale M
Recenti Prog Med; 2013; 104(7-8):415-9. PubMed ID: 24042420
[TBL] [Abstract][Full Text] [Related]
9. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
10. Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms?
Shibru D; Hwang J; Khanafshar E; Duh QY; Clark OH; Kebebew E
Cancer; 2008 Sep; 113(5):930-5. PubMed ID: 18661512
[TBL] [Abstract][Full Text] [Related]
11. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.
Keutgen XM; Filicori F; Crowley MJ; Wang Y; Scognamiglio T; Hoda R; Buitrago D; Cooper D; Zeiger MA; Zarnegar R; Elemento O; Fahey TJ
Clin Cancer Res; 2012 Apr; 18(7):2032-8. PubMed ID: 22351693
[TBL] [Abstract][Full Text] [Related]
12. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.
Puskas LG; Juhasz F; Zarva A; Hackler L; Farid NR
Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(2):177-86. PubMed ID: 16171553
[TBL] [Abstract][Full Text] [Related]
13. The molecular diagnosis and management of thyroid neoplasms.
Theoharis C; Roman S; Sosa JA
Curr Opin Oncol; 2012 Jan; 24(1):35-41. PubMed ID: 22123232
[TBL] [Abstract][Full Text] [Related]
14. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings.
Sapio MR; Posca D; Raggioli A; Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Troncone G; Caleo A; Rossi G; Fenzi G; Vitale M
Clin Endocrinol (Oxf); 2007 May; 66(5):678-83. PubMed ID: 17381488
[TBL] [Abstract][Full Text] [Related]
15. BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma.
Chang H; Lee H; Yoon SO; Kim H; Kim A; Kim BH
Hum Pathol; 2012 Jan; 43(1):89-95. PubMed ID: 21774961
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of ancillary methods for diagnosis, prognosis and targeted therapy in thyroid pathology.
Bozec A; Ilie M; Lassalle S; Hofman V; Benaim G; Long E; Santini J; Hofman P
Curr Med Chem; 2013; 20(5):639-54. PubMed ID: 23298138
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma.
Sapio MR; Guerra A; Posca D; Limone PP; Deandrea M; Motta M; Troncone G; Caleo A; Vallefuoco P; Rossi G; Fenzi G; Vitale M
Endocr Relat Cancer; 2007 Dec; 14(4):1089-97. PubMed ID: 18045960
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.
Nikiforova MN; Nikiforov YE
Expert Rev Mol Diagn; 2008 Jan; 8(1):83-95. PubMed ID: 18088233
[TBL] [Abstract][Full Text] [Related]
19. Genetic markers differentiating follicular thyroid carcinoma from benign lesions.
Freitas BC; Cerutti JM
Mol Cell Endocrinol; 2010 May; 321(1):77-85. PubMed ID: 19932149
[TBL] [Abstract][Full Text] [Related]
20. Circulating thyroid cancer markers.
Gupta M; Chia SY
Curr Opin Endocrinol Diabetes Obes; 2007 Oct; 14(5):383-8. PubMed ID: 17940468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
